|Announcement Title ||General Announcement|
|Date & Time of Broadcast||19-Feb-2018 12:38:28|
|Announcement Sub Title||New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody|
|Submitted By (Co./ Ind. Name)||Glenmark Pharmaceuticals Limited|
|Designation||Company Secretary & Compliance Officer|
|Effective Date and Time of the event||19/02/2018 10:00:00|
|Description (Please provide a detailed description of the event in the box below)||Sub: Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting|
With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.
Request you to kindly take the same on record.